Gastrointestinal Stromal Tumors News and Research

RSS

Combination drug treatment could be effective against malignant peripheral nerve sheath tumors

A combination of two cancer drugs could be effective against malignant peripheral nerve sheath tumors (MPNSTs) -; soft tissue tumors that are stubbornly resistant to chemotherapy and radiation -; according to a laboratory study led by researchers at the Johns Hopkins Kimmel Cancer Center.

31 Jan 2024

Researchers report genomic profiling from more than 110,000 tumors

Researchers analyzed data from the latest public release of the GENIE project of the American Association for Cancer Research.

19 Jul 2022

AI and machine learning could improve cancer diagnosis through biomarker discovery

Artificial intelligence (AI), deep learning (DL), and machine learning (ML) have transformed many industries and areas of science.

1 Mar 2022

Combination of two targeted drugs shows "clinically meaningful" activity in some malignant brain tumors

A combination of two targeted cancer drugs showed unprecedented, "clinically meaningful" activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.

25 Nov 2021

Telehealth’s limits: Battle over state lines and licensing threatens patients’ options

If you live in one state, does it matter that the doctor treating you online is in another? Surprisingly, the answer is yes, and the ability to conduct certain virtual appointments may be nearing an end.

31 Aug 2021

Specific cell-to-cell communication associated with progression of gastrointestinal stromal tumors

Gastrointestinal stromal tumors (GISTs) are a subytpe of cancers known as sarcomas. GIST is the most common type of sarcoma with approximately 5,000 to 6,000 new patient cases annually in the United States.

18 Feb 2021

New technology uses near-infrared imaging and machine learning to find hidden tumors

Tumors can be damaging to surrounding blood vessels and tissues even if they're benign. If they're malignant, they're aggressive and sneaky, and often irrevocably damaging. In the latter case, early detection is key to treatment and recovery.

3 Feb 2021

Genetic testing is cost-effective, beneficial for newly diagnosed patients with metastatic GIST

Because gastrointestinal stromal tumors (GIST) are sensitive to the targeted small molecule therapy imatinib, oncologists tend to treat all patients with metastatic GIST with this drug. However, because this rare type of cancer is caused by different genetic mutations, imatinib does not help all patients equally.

28 Sep 2020

Improving cancer therapies by exploiting drug resistance in cancer

News-Medical talks to Professor David Thomas about his recent research identifying the mechanisms behind cancer cells developing resistance to drugs.

23 Jun 2020

Study reveals novel druggable driver gene in human gastrointestinal stromal tumors

Sarcomas - cancers that arise from transformed mesenchymal cells (a type of connective tissue) - are quite deadly. Gastrointestinal stromal tumors are the most common human sarcoma and are initiated by activating mutations in the KIT receptor tyrosine kinase.

24 Oct 2019

Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced the presentation today of updated preliminary results from its ongoing Phase 1 clinical study of DCC-2618, the company's broad-spectrum KIT and PDGFRα inhibitor, in patients with gastrointestinal stromal tumors as a proffered paper presentation at the European Society of Medical Oncology 2018 Congress in Munich, Germany.

22 Oct 2018

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

The U.S. Food and Drug Administration today approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy).

17 Nov 2017

Research identifies new gene fusions and mutations linked to GIST tumors

Researchers at UC San Diego Moores Cancer Center, with colleagues from Memorial Sloan Kettering Cancer Center and Fox Chase Cancer Center, have determined that a specific region of the small bowel, called the duodenal-jejunal flexure or DJF, shows a high frequency of gastrointestinal stromal tumors (GISTs) with mutations of the NF1 gene

18 Aug 2017

Colorectal cancer deaths on the rise among Americans: JAMA study

A new study from the American Cancer Society has found that more people living in the United States of America are dying from colon and rectal cancers around the age of 50 years when they are supposed to officially begin screening for these cancers. The new study is published in the JAMA, the Journal of the American Medical Association.

10 Aug 2017

Researchers identify DNA repair deficiency in many types of solid tumors

A new investigation of more than 48,000 stored tumor samples finds evidence of a key deficiency in a repair mechanism designed to keep DNA from being mutated and causing cancer.

18 May 2017

Stivarga receives expanded FDA approval for treatment of liver cancer

The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib.

28 Apr 2017

Small intestine tumors linked to improved survival in adolescents and young adults

Gastrointestinal stromal tumors are tumors that arise is the wall of the digestive tract, and most often occur in the stomach or small intestine. Though more common in later in life, GISTs can occur in adolescents and young adults under 40 years old as well.

19 Jan 2017

Researchers identify new gene fusions and mutations linked to subset of GIST patients

In recent years, researchers have identified specific gene mutations linked to gastrointestinal stromal tumors (GIST), which primarily occur in the stomach or small intestine, with 5,000 to 6,000 new cases per year in the United States.

16 Dec 2016

Researchers discover Hedgehog signaling pathway is key to formation of gastrointestinal stromal tumors

Researchers at University of California San Diego School of Medicine and Mayo Clinic provide the first evidence that the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors (GIST), which are frequently driven by the KIT oncogene.

1 Nov 2016

Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein

Cancer remains a leading cause of death worldwide, and the global cancer burden is expected to increase by 70 percent over the next two decades.

14 Jul 2016